Treatment of High-Risk T-NHL with Stem Cell Transplantation: A Single Center Experience

[1]  M. Duchosal,et al.  High-dose therapy and autologous hematopoietic stem cell transplant in T-cell lymphoma: a single center experience , 2014, Leukemia & lymphoma.

[2]  Richard J. Jones,et al.  Outcomes of Allogeneic Blood or Marrow Transplantation for Peripheral T-Cell Lymphoma. , 2012 .

[3]  C. Schmidt,et al.  Treatment of splenic marginal zone lymphoma of the CNS with high-dose therapy and allogeneic stem cell transplantation , 2012, Experimental Hematology & Oncology.

[4]  Y. Kwong,et al.  SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. , 2012, Blood.

[5]  D. Baronciani,et al.  Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect , 2012, Leukemia.

[6]  K. Savage.  Therapies for peripheral T-cell lymphomas. , 2011, Hematology. American Society of Hematology. Education Program.

[7]  E. D. Jacobsen,et al.  A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides/Sezary syndrome. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  J. Vose,et al.  Peripheral T-cell lymphoma. , 2011, Blood.

[9]  P. Corradini,et al.  Allogeneic transplantation for lymphoma: long-term outcome , 2010, Current opinion in hematology.

[10]  M. Sorror,et al.  Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with T‐cell and natural killer‐cell lymphomas , 2010, British journal of haematology.

[11]  N. Schmitz,et al.  Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  N. Schmitz,et al.  Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  N. Schmitz,et al.  High-Dose Therapy and Autologous Stem-Cell Transplantation in Angioimmunoblastic Lymphoma: Complete Remission at Transplantation Is the Major Determinant of Outcome—Lymphoma Working Party of the European Group for Blood and Marrow Transplantation , 2008 .

[14]  J. Okamura,et al.  Allogeneic Stem Cell Transplantation for Adult T-Cell Leukemia/Lymphoma , 2007, International journal of hematology.

[15]  D. Niederwieser,et al.  Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkologie OSHO-53 phase II study. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  T. Barbui,et al.  Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation , 2006, Leukemia.

[17]  H. Einsele,et al.  Central venous catheter-related infections in hematology and oncology , 2008, Annals of Hematology.

[18]  H. Einsele,et al.  Antimicrobial prophylaxis in allogeneic bone marrow transplantation. Guidelines of the infectious diseases working party (AGIHO) of the german society of haematology and oncology. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  H. Einsele,et al.  Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. , 2005, Blood.

[20]  M. Maris,et al.  Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. , 2004, Blood.

[21]  M. Boccadoro,et al.  Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  A. Barrett,et al.  Review Articles (434 articles) , 2003 .

[23]  M. Freund,et al.  Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation. , 2004, Blood.

[24]  E. Kimby,et al.  Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation. , 2003, Haematologica.

[25]  P. Gaulard,et al.  Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). , 1998, Blood.

[26]  N. Kröger,et al.  High dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  G. Vogelsang.  Acute and chronic graft‐versus-host disease , 1993, Current opinion in oncology.

[28]  F. Appelbaum,et al.  Regimen-related toxicity in patients undergoing bone marrow transplantation. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  P. Neiman,et al.  CLINICAL MANIFESTATIONS OF GRAFT‐VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL‐A-MATCHED SIBLING DONOR,S , 1974, Transplantation.